Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Robert Mancini, PharmD, explains the viral infections commonly seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.
Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple Myeloma
Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.
Infection Patterns of Bispecific Antibodies in Multiple Myeloma Treatment
Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.
Overview of Bispecific Antibodies in Multiple Myeloma Treatment
Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.
